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Background: Mutations in the CTSA gene, that encodes the protective protein/cathepsin A or PPCA, lead to the
secondary deficiency of β-galactosidase (GLB1) and neuraminidase 1 (NEU1), causing the lysosomal storage disorder
galactosialidosis (GS). Few clinical cases of GS have been reported in the literature, the majority of them belonging
to the juvenile/adult group of patients.
Methods: The correct nomenclature of mutations for this gene is discussed through the analysis of the three
PPCA/CTSA isoforms available in the GenBank database. Phenotype-genotype correlation has been assessed by
computational analysis and review of previously reported single amino acid substitutions.
Results: We report the clinical and mutational analyses of four cases with the rare infantile form of GS. We
identified three novel nucleotide changes, two of them resulting in the missense mutations, c.347A>G
(p.His116Arg), c.775T>C (p.Cys259Arg), and the third, c.1216C>T, resulting in the p.Gln406* stop codon, a type of
mutation identified for the first time in GS. An Italian founder effect of the c.114delG mutation can be suggested
according to the origin of the only three patients carrying this mutation reported here and in the literature.
Conclusions: In early reports mutations nomenclature was selected according to all CTSA isoforms (three different
isoforms), thus generating a lot of confusion. In order to assist physicians in the interpretation of detected
mutations, we mark the correct nomenclature for CTSA mutations. The complexity of pathology caused by the
multifunctions of CTSA, and the very low numbers of mutations (only 23 overall) in relation to the length of the
CTSA gene are discussed.
In addition, the in silico functional predictions of all reported missense mutations allowed us to closely predict the
early infantile, late infantile and juvenile phenotypes, also disclosing different degrees of severity in the juvenile
phenotype.Background
The protective protein/cathepsin A (PPCA or CTSA) is a
multifunctional lysosomal enzyme with distinct protective
and catalytic function [1].
The mature form of PPCA/CTSA, consisting of a 32/
20 kDa disulfide-linked two chain product, is found in a
high molecular weight, lysosomal multienzyme complex
(LMC) together with two other glycosidases, β-galactosidase
(GLB1) and N-acetyl alpha neuraminidase 1 (NEU1)* Correspondence: amelia.morrone@unifi.it
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reproduction in any medium, provided the or[2-4]. A supposed role of N-acetylgalactosamine-sulfate
sulfatase (GALNS) in such complex [5] still lacks
interpretation.
Association with PPCA/CTSA in an early biosynthetic
compartment ensures the correct lysosomal transport,
activation and stability of GLB1 and NEU1 [6]. This de-
fines the enzyme protective function. On the other hand,
studies of the physiological role of PPCA/CTSA as a serine
carboxypeptidase/deamidase/esterase demonstrated a role
of the enzyme in the inactivation of selected neuropeptides,
like substance P, oxytocin and endothelin I [7]. PPCA/
CTSA is also responsible for the proteolytic inactivation of
Lysosome-associated membrane protein (LAMP)2a, a lyso-
somal integral membrane protein involved in chaperonel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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way of protein degradation [8].
Mutations in the CTSA gene are the cause of the
lysosomal storage disease galactosialidosis (GS). Loss of
function of PPCA/CTSA results in the secondary com-
bined deficiency of GLB1 and NEU1, which is the bio-
chemical hallmark of the disease. Patients with GS
present with a broad spectrum of clinical manifestations,
but are usually classified as early infantile, late infantile
or juvenile/adult type based on the age of onset and se-
verity of their symptoms.
The early infantile phenotype, the most severe form
of the disease, usually presents with hydrops fetalis,
cherry red spots, visceromegaly, psychomotor delay,
coarse facies, skeletal dysplasia, and early death. Late
infantile forms are characterized by corneal clouding,
cardiac involvement, visceromegaly and, rarely, psy-
chomotor retardation. Most patients with the milder
juvenile/adult form, exhibited myoclonus, ataxia, neuro-
logical deterioration, angiokeratoma, and absence of
visceromegaly [9,10].
It is still unclear whether the catalytic function of
PPCA/CTSA contributes to particular clinical signs of
GS. In this respect, impaired LAMP2a degradation due
to PPCA/CTSA deficiency may be linked to the low
weight of affected individuals [8] and the lack of inacti-
vation of specific bioactive peptides may play a role in
the regulation of the blood pressure [7].
In addition, it has been previously suggested that PPCA/
CTSA plays a role in elastic fibers assembly, through its
association with the enzymatically inactive, spliced variant
of β- galactosidase, known as the elastin binding protein
(EBP). Because EBP acts as an intracellular chaperone for
tropoelastin, facilitating the trafficking and deposition of
elastic fibers [11], lack of PPCA/CTSA in GS can be ac-
companied by alterations in elastogenesis, affecting the
cardiovascular and respiratory systems [7,12,13]. This is
especially true for GS patients with a longer survival, as
they need periodic assessment of their pulmonary func-
tion and emphysema, linked to a defect in elastic fiber
assembly [10].
Because PPCA/CTSA is present in the LMC, muta-
tions altering the folding of one protein in the complex
can influence the other components as well [14,15].
Multiple sequence alignments may predict functional
sites or domains that may favor intra- or inter-molecular
interactions within the LMC. Analogously, structural
web applications may predict an amino acid substitution
as disease-causing or neutral in humans, and it could
suggest the molecular causes of a disease. For instance,
gain of helical propensity or loss of a phosphorylation
site or disorder to order transitions caused by Molecular
Recognition Features (Morf ), specific regions of proteins
that exhibit molecular binding functions [16].A total of 23 CTSA gene mutations have been reported
(HGMD professional https://portal.biobase-international.
com/cgi-bin/portal/login.cgi). These include deletions, mis-
sense and splicing mutations, but no nonsense mutations.
Alternatively spliced transcripts of the CTSA gene have
been described, and at least three CTSA mRNA sequences
have been deposited in the GenBank database (RefSeq,
http://www.ncbi.nlm.nih.gov/gene/5476). In early reports
mutations nomenclature was selected according to all
CTSA isoforms, which generated confusion in the way
CTSA mutations were reported. Some mutations were
numbered based on a PPCA sequence that was either 46
(missing all the amino acids of the signal peptide) [17-20]
or 18 [13,21] amino acids shorter than that reported in the
HGMD professional database.
In order to assist physicians in the interpretation of
detected mutations, we review and discuss previously
reported CTSA transcripts, underlying erroneous or
current nomenclature. We also present the molecular
and clinical assessment of four new observations of the
rare infantile form of GS. Computational analyses to
predict a role of the new and/or previously reported
missense mutations are discussed in order to address
the clinical and molecular implications of the CTSA de-
fects in GS patients.
Methods
Cell culture
Skin fibroblasts from patient 3, and normal controls were
cultured in Ham’s F-10 medium supplemented with 10%
fetal bovine serum and antibiotics. Cell lines from the
remaining patients we report are no longer available.
Enzyme assays
The Micro BCA protein Assay kit (Pierce Rockford, USA)
was used to set up the starting proteins used in each en-
zyme assay. GLB1, NEU1, PPCA and GALNS activities
were measured in cell lysates of fibroblasts and/or leuko-
cytes using commercially available fluorogenic substrates
(Moscerdam substrates, Netherlands) and according to
manufacturer’s instructions (www.moscerdam.com). For
NEU1 assays: cells lysates, BCA measurements and assays
were performed in fresh samples, lysed by pipetting.
PCR amplification of genomic DNA and informed
consents
Genomic DNA was extracted from the patient’s fibro-
blasts and/or lymphocytes using standard methods. The
genomic fragments covering all 15 exons and the exon/
intron boundaries of the CTSA gene were amplified by a
set of primers located in flanking intronic sequences.
PCR amplifications were performed under the previously
reported conditions [13]. Informed consents for genetic
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DNA sequencing
PCR fragments were separated on a 2% agarose gel and
the bands were visualized using a UV transilluminator.
DNA products were purified by Nucleospin Extract kit
(Macherey-Nagel, Düren, Germany), following the manu-
facturer’s protocol. The double-stranded purified products
were used for direct sequencing with the same PCR amp-
lification primers. Sequencing reactions were performedTable 1 Clinical findings of galactosialidosis patients
Patient 1 2
Ethnic Origin Caucasian Caucasian
Sex F M
Clinical Phenotype EI EI
Age at Onset perinatal perinatal
Fetal hydrops + -
Edema + -
Presentation fetal hydrops,
developmental delay
failure to thrive si
Age at diagnosis 4 m 17 m
Psychomotor delay + +
Hypotonia + -
Course facies + +
Eye lens clouding -
Hepatosplenomegaly + +
Cardiac involvement + -
Skeletal involvement - +
Renal involvement - no
Seizures no no
Muscle involvement no no
Brain MRI - -
GLB1 activity
(nmol/mg/h)
27 (NV 391-2397) on
fibroblasts
61 (NV 391-239
fibroblast
NEU1 activity
(nmol/mg/h)
0,1 (NV 5,1-48) on
fibroblasts
0,76 (NV 5,1-4
fibroblast
Other - -
Alive (age) deceased deceased
CTSA molecular
analysis
c.448C > A (p.Val150Met)/
c.1216C > T (p.Gln406*)
c.775 T > C (p.Cys
c.775 T > C (p.Cy
Legend: F female, M male, EI early infantile, + presence of the symptom, - not availa
are evidenced.using the ABI PRISM 3130 Genetic Analyzer (Applied
Biosystems, Foster City, U.S.A.) as recommended by the
manufacturer.
Screening of new mutations and in silico analyses
The 1000 Genomes project database (http://www.1000
genomes.org/) including all human genetic variations
from the dbSNP short genetic variations database (http://
www.ncbi.nlm.nih.gov/omim) did not report the fre-
quency of the newly presented point mutations. In order
to analyse the actual frequency of such variants in the3 4
Caucasian Caucasian
M M
EI EI
perinatal perinatal
+ -
+ + (1 month of age)
nce birth fetal hydrops respiratory distress, inguinal
hernia, telangectasias,
equinovarus feet,
arthrogryposis, gingival
hypertrophy
1 m post-mortem
+ +
+ +
+ +
- hypopigmentated fundus
+ -
+ +
- +
no no
no no
no no
enlarged ventricles,
hyperintense white matter
striato thalamic
vasculopathy, widened
periencephalic spaces
7) on
s
143 (NV 400-1100) on
fibroblasts; 12 (NV 90-250)
on leukocytes
44,1 (NV 291-525) on
fibroblasts
8) on
s
0 on fibroblasts (NV 17- 68)
and leukocytes (NV 0,37- 3)
2,4 (NV 66-197) on
fibroblasts
dysphagia telangectasias,
inguinal hernia, recurrent
pleural effusion and ascites,
clubfeet
failure to thrive, frequent
vomiting, ascites,
hypertelorism,
thrombocytopenia
deceased at 3 m deceased at 4 m, 22d
259Arg)/
s259Arg)
c.114delG/c.347A > G
(p.His116Arg)
c.114delG/c.114delG
ble data; no normal, m months, d days, NV normal values. New mutations
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DNA samples was analysed by sequencing analysis. The
PCR fragments were amplified by the genomic primers
reported earlier [13]. In addition, the single amino acid
substitutions were also analysed by SIFT (http://sift.jcvi.
org/www/SIFT_aligned_seqs_submit.html) and PolyPhen
(http://genetics.bwh.harvard.edu/pph/) multiple sequence
alignments of CTSA related proteins.
The functional effect of novel missense mutations on
resulting CTSA enzymes was predicted by MutPRed
(http://mutpred.mutdb.org/) web site.
Results
Clinical and biochemical data of the four GS patients here
reported
The clinical data and mutation analysis of the new GS
patients reported here are summarised in Table 1. All
patients showed vacuolated lymphocytes in peripheral
blood smears. A marked reduction of GLB1 and absence
of NEU1 activity confirmed the diagnosis of GS on fibro-
blasts and/or lymphocytes (Table 1). Biochemical data
were performed in different accredited diagnostic labora-
tories (thus control values are different), but NEU1 ac-
tivity was nearly absent in all patients while patients’
GLB1 activity ranged from 2 to 19% of normal values.
CTSA activity, measured in Pt3 fibroblasts, was also
completely absent (normal value 191- 482 nmol/mg/
min). In contrast, GALNS assays performed in both lym-
phocytes and fibroblasts of Pt3 was within the normal
range. Indeed, functional protein association networks as
Gene Mania (www.genemania.org/) and String (http://
string-db.org/) showed that GALNS interacts at least
with NEU1 but not directly with PPCA/CTSA inside the
LMC (Figure 1).Figure 1 Action view of the physiological interactions between GALN
B. Gene Mania prediction.Common symptoms in all four patients included facial
dysmorphisms, hypotonia, developmental delay, failure
to thrive, liver-spleen-megaly and ascites (Table 1). Re-
spiratory distress and cardiac involvement, when investi-
gated, were also observed. Cardiomyopathy was detected
in Pt1. Pt3 was intubated for respiratory failure at birth.
He also exhibited reduced cardiac contractility and
cardiac dilatation with stiff and dilated inferior vena cava
at the 2nd day of life. Pt4 presented with hypertrophic
interventricular septum, which evolved into dilated car-
diomyopathy. Skeletal involvement was also noticed in
this patient since he was one week old. He exhibited a
rarefaction of femoral, tibial and heels metaphysis to-
gether with horizontalysed acetabula. Brain magnetic
resonance imaging performed in Pt3 and 4, identified al-
terations in brain structure and blood flow (Table 1).In silico evaluation of CTSA isoforms and mutation
nomenclature
In order to avoid confusion in mutation nomenclature,
we critically examine reported CTSA variants (RefSeq,
http://www.ncbi.nlm.nih.gov/gene/5476). Transcript var-
iants and their differences are outlined in Figure 2.
Since Variant 1 has been chosen as the reference
sequence for the mutation nomenclature in HGMD pro-
fessional (https://portal.biobase-international.com/cgi-bin/
portal/login.cgi), reported mutations have to be listed
according to NM_000308.2 CTSA variant (variant 1, iso-
form a), as in the current report.Sequencing analysis of the CTSA gene
The results of mutation analyses of the GS patients
reported here are summarised in Table 1.S, GLB1, NEU1 and PPCA/CTSA in human cells. A. String prediction;
Figure 2 Schematic representation of the CTSA gene transcript variants (from www.ncbi.nlm.nih.gov/). The reference transcript for the
correct mutations nomenclature is indicated by an arrow. A. Transcript Variant 1 encoding the longer isoform (a) of 498 amino acids
(NM_000308.2) is the gene transcript selected by HGMD for mutations nomenclature. Transcript Variant 2 has an alternate splice site in the 5′
region, which results in a downstream AUG start codon, as compared to variant 1 (NM_001127695.1). The resulting isoform (b), gives rise to 480
amino acids. Transcript Variant 3 lacks an alternate in-frame exon in the 5′ coding region, compared to variant 1 (NM_001167594.1). B. The main
differences between the three transcripts are outlined.
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of all 15 exons, including the signal peptide sequence
and the intron/exon boundaries of the patients’ CTSA gene.
Three new point mutations were identified: c.1216C>T
(p.Gln406*) c.775T>C (p.Cys259Arg) and c.347A>G
(p.His116Arg). Computational analyses of the known point
mutations (reported in HGMD professional database),
and of the new point mutations identified are reported
in Table 2.
Pt 1 and Pt3 are both heterozygous for a nonsense
mutation and a deletion, thus their second allelic muta-
tions, respectively p.Val150Met and p.His116Arg, can be
linked to the severe early infantile phenotype (Tables 1
and 2).
In silico CTSA functional/structure predictions of missense
mutations
In Table 2 we have reviewed the clinical phenotypes and
genotypes of previously reported GS patients and included
the functional/structural predictions of newly identified as
well as previously described CTSA missense mutations
(Table 2).
The clinical features of previously reported homozy-
gous patients allowed for a close genotype- phenotype
correlation (Table 2). The p.Tyr413Cys mutation was
identified in both early infantile and adult patients. How-
ever, in the adult patient it was detected in combination
with the c.746 + 3A > G change, reported as a mild mu-
tation in homozygotes adult patients [21,24]. Thus, the
p.Tyr413Cys mutation underlies the severe phenotype.
The p.Tyr267Asn was detected in a “variant” form of an
early infantile patient without neurological involvement
[21]. The same mutation was later identified in a patient
with the late infantile form of the disease [22] and
marginal neurological involvement, if any [9,20]. The
p.Gln67Arg was first reported in a juvenile patient [21],in combination with a mild mutation. The early infantile
phenotype was linked to such mutation by structure
analysis [19], which was confirmed by a subsequent clin-
ical report [25].
Prediction tools indicated that the p.Ser69Val,
p.Val83Arg and p.Gly103Val, detected in juvenile pa-
tients in combination with mild mutations or reported in
non-assigned clinical phenotypes, can be linked to severe
outcomes. Coarse facies, hepatosplenomegaly, growth re-
tardation and an unusual renal symptomatology were
described in a 9-year-old patient who was compound het-
erozygous for the p.Gly103Val and p.Arg442Trp muta-
tions [18]. Since this patient had normal neurological
development, the diagnosis of late-infantile GS can be
supposed and probably linked to the p.Arg442Trp muta-
tion. It was reported earlier that the p.Tyr267Asn corre-
lated with a more severe phenotype than that associated
with the p.Phe458Val [22] unless both mutations were
found in the juvenile/adult form of the disease. This
assumption seems to be correct based on previously
reported structure prediction [19] (Table 2).
Discussion
GS is a rare lysosomal storage disease with most of the
described patients having the juvenile/adult form [9,10].
The prevalence of GS is unknown; more than 100 obser-
vations have been reported but only 23 mutations have
been identified so far, including point-mutations and
rearrangements, but no nonsense mutations [9,10]. Here
we report the first case of GS carrying a CTSA gene
nucleotide change leading a stop codon mutation. The
rarity of such mutation type in the GS patient popula-
tion is likely attributable to the rare incidence of the
early infantile form of the disease.
We also describe two new missense mutations:
c.347A>G (p.His116Arg), and c.775T>C (p.Cys259Arg).
Table 2 CTSA gene point mutations and significance
Mutation Ex. Phe. Mut Pred computational analysis PPCA three-dimensional
reported outputs (Zhou et al.
1996 [22]; Rudenko et al. 1998
[19]; Takiguchi et al 2000 [23])
Philogenetic
conservation
Ref.
P. Actionable hypotheses Confident hypothesis Very confident hypothesis SIFT
score
Polyphen
score(g > 0.5, p < 0.05) (g > 0.75, p < 0.05) (g > 0.75, p < 0.01)
p.Gln67Arg 2 EI 0.941 Gain of MoRF binding Drastically alters folding and
stability
T (0,07) D (0,996) Shimmoto 1993 [21]
p.Ser69Tyr 2 EI 0.942 Loss of disorder Drastically alters folding and
stability
D (0,00) D (1,000) Zhou 1996 [22]
p.Val83Arg 2 EI 0.957 Gain of methylation Gain of disorder Drastically alters folding and
stability
D (0,00) D (1,000) Shimmoto 1993 [21]
p.Gly103Ser 3 EI 0.974 D (0,00) D (1,000) Groener 2003 [17]
p.Gly103Val 3 EI 0.962 D (0,00) D (1,000) Kiss 2008 [18]
p.Ser108Leu 3 EI 0.962 Loss of disorder Drastically alters folding and
stability
D (0,00) D (1,000) Shimmoto 1993 [21]
p.His116Arg 3 EI 0.712 Gain of methylation T (0,45) D (0,999) This work
p.Val150Met 5 EI 0.947 Loss of catalytic residue Drastically alters folding and
stability
D (0,00) D (1,00) Zhou 1996 [22]
p.Leu254Pro 8 EI 0.921 Loss of stability; Gain of
catalytic residue
Drastically alters folding and
stability
D (0,00) D (1,000) Zhou 1996 [22]
p.Cys259Arg 8 EI 0.726 Gain of disorder; Loss
of ubiquitination
D (0,00) D (1,00) This work
Tyr267Asn 8 LI 0.798 Gain of disorder; Loss of
stability
Milder effect on protein function
and residual mature PPCA
D (0,04) B (0,189) Shimmoto 1993 [21]
Tyr413Cys 13 EI 0.933 Drastically alters folding and
stability
D (0,00) D (1,000) Shimmoto 1993 [21]
p.Met424Tyr 13 EI/LI 0.804 Generation of a glycosylation site
and destabilization of
dimerisation
D (0,01) B (0,214) Zhou 1996 [22]
p.Arg442Trp 14 LI 0.697 D (0,01) D (1,000) Kiss 2008 [18]
p.Gly457Ser 14 EI 0.948 Drastically alters folding and
stability
D (0,01) D (1,000) Zhou 1996 [22]
p.Phe458Val 14 LI 0.867 Milder effect on protein function,
destabilization or defective
dimerisation of the precursor
T (0,15) D (0,990) Zhou 1991 [20]
p.Lys471Glu 14 J/A 0.893 Loss of methylation Milder effect on protein function,
destabilization or defective
dimerisation of the precursor
T (0,21) D (1,000) Takiguchi 2000 [23]
Legend: P Probability of deleterious mutation, Ex exon, T Tolerated, D Deleterious, B Benign, MoRFs Molecular Recognition Features, Phe Clinical phenotype, EI early infantilem LI late infantile, J/A juvenile/adult.
Mutations detected in the patients here reported are underlined.
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with the c.114delG, a deletion found at the homozygous
level also in Pt4 and previously reported in an unrelated
patient originating from the same area of central Italy [13].
Since this mutation was not reported in patients with other
origin in the literature and due to the small number of pre-
viously reported mutations, a founder effect for such one-
base deletion can be hypothesized.
As mentioned earlier, three different CTSA cDNAs
transcripts are deposited in the GenBank database, thus
the past literature on CTSA mutations referred randomly
to the different isoforms, which has been the source of
confusion. For example, the p.Val150Met mutation has
been first reported as p.Val104Met [22] and then reported
as p.Val132Met [23]. We would like to stress the import-
ance of having the CTSA mutation nomenclature homolo-
gated to the HGMD professional guide lines, which
choose CTSA Variant 1 as the reference sequence for mu-
tation nomenclature of the CTSA resulting protein.
To deepen the correlation between mutations and their
effects on the CTSA protein structure we performed com-
putational analyses using in silico tools based on phylo-
genetic alignments and functional/structural predictions.
Multiple alignments of related sequences among organ-
isms and structural web applications help to identify re-
gions or domains that are conserved and may indicate
functional constraints.
We found computational analyses to be helpful in
improving the determination of the pathognomonic ef-
fects of newly identified nucleotide variants and genotype-
phenotype correlations. This method has been particularly
useful in the case of compound heterozygous mutations
reported in mild affected patients or when clinical data
are insufficient, i.e. if expression studies and/or structural
analysis of compound heterozygous mutations are not
available. The reverse process: from a described phenotype
to computational analysis showed a good correlation be-
tween in silico predictions and mutation severity.
We want to emphasize that predictive functional/struc-
tural analyses of mutant proteins and phenotypes are
closely related, often providing clearcut indications on the
specific form of the disease (early infantile, late infantile,
juvenile). We found such analyses of use to predict the
extent of disease severity related to two mutations p.
Tyr267Asn and p.Phe458Val found in juvenile GS pa-
tients. In contrast, phylogenetic comparisons in most
cases provide indications that are limited to the patho-
genic/non-pathogenic effects of mutations without further
details. Thus, the combination of multiple computational
analyses is an effective strategy.
CTSA binds and regulates GLB1 and NEU1 inside ly-
sosomes [6]. Structure predictions, identifying mutations
that alter Molecular Recognition Features (MoRFs) or re-
sult in gain or loss of function in CTSA, could accordinglyprovide information on the three-dimensional structure of
the complex proteins. These findings might provide indi-
cations on the pathogenetic effects of mutations and on
the interactions between the proteins within the LMC.
Known and predicted protein-protein interactions eval-
uated by String and GeneMania prediction software
evidenced that PPCA/CTSA does not directly interact
with GALNS thus corroborating the molecular data show-
ing that the PPCA/CTSA deficit does not affect the
GALNS activity in Pt3. However our findings can not ex-
clude the involvement of GALNS in the LMC after the
binding with NEU1.
The protective function of PPCA dramatically affects
both GLB1 and NEU1, leading to a broad range of
clinical manifestations, worsening with age [2]. PPCA
defects causes both glycosidases to malfunction, indeed
early infantile forms of GS share clinical signs observed
in the infantile forms of both GM1 gangliosidosis and
type II sialidosis [19]. In addition, altered catalytic activ-
ity of PPCA could contribute to the variability of symp-
toms due to the potential esterase/deamidase activity of
PPCA in platelets, endothelial cells, heart and kidney [3].
A cardiovascular role of PPCA could also be linked to the
altered function of EBP due to structural mutations of
PPCA as its binding partner at the plasma membrane
[11]. Our prediction tools identified only one CTSA
amino acid change (p.Val150Met) that could affect its
catalytic site. This mutation, detected in combination with
the p.Gln406* change, is linked to the early infantile
phenotype with fetal hydrops and cardiac involvement.
CTSA gene, spanning about 43.000 bp and containing
15 exons, is about twice the average length of human
genes. However, reported CTSA mutations are a very
low number. The reason for which a region or site have
a higher or lower mutation rate is poorly understood,
except in the case of CpG islands where cytosine can
become methylated and unstable, leading to a higher
rate of mutation [26].
The majority of CTSA genetic lesions occur at posi-
tions that are evolutionarily conserved [27], and non-
variable sites may indicate protein sequences under
more selective constraints [28]. Thus, the PPCA/CTSA
paradigm could be useful both at genetic level, identifying
base composition bias around CpG dinucleotides, distri-
bution and rate of single nucleotide polymorphisms, and
at functional level, giving structural consequences of mu-
tated amino acids and regions.
Conclusions
In early reports mutations nomenclature was selected
according to all CTSA isoforms (three different isoforms),
thus generating a lot of confusion. In order to assist physi-
cians in the interpretation of detected mutations, we
underline the correct nomenclature for CTSA mutations.
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tosialidosis are here detailed and three novel nucleotide
changes were identified, one of them resulting in a stop
codon, a type of mutation identified for the first time in
galactosialidosis.
We also present some data on brain magnetic reson-
ance, never detailed so far in galactosialidosis. Likewise,
predictive functional/structural analyses of mutant pro-
teins and phenotypes have been shown to be closely re-
lated, often giving clearcut indications on the specific
form of the disease (early infantile, late infantile, juvenile).
The complexity of the clinical phenotypes in GS re-
flects the dual functions of PPCA/CTSA (catalytic and
regulating/protective) and thus its functional role in both
lysosomal and cell membranes. Further three-dimensional
studies can provide additional information on functional
domains, on protein-protein interactions within the lyso-
somal and the non-lysosomal complexes and on the onset
and progression of symptoms.Abbreviations
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